OptiNose (NASDAQ: OPTN) reported Q1 EPS of ($0.17), $0.01 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $11.85 million versus the consensus estimate of $9.95 million.

The Company expects XHANCE net revenues for the full year of 2023 to be between $62.0 to $68.0 million. In addition, the Company expects the full year 2023 XHANCE average net revenue per prescription to be approximately $200.

For earnings history and earnings-related data on OptiNose (OPTN) click here.